Placebo News and Research

RSS

Stem cells used to combat COVID-19 pneumonia

The novel coronavirus first emerged in December 2019, and since then, it rippled across 180 countries, affecting hundreds of thousands of people. Amid the coronavirus disease (COVID-19) pandemic, many people are looking for answers. Scientists are racing to find a treatment that can help save lives. Now, a team of scientists has suggested that stem cell therapy can help fight the deadly infection.

1 Apr 2020

FDA to trial malaria drugs Chloroquine and Hydroxychloroquine for COVID-19

The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.

31 Mar 2020

Novel, affordable pneumonia vaccine tested in human patients

A novel vaccine against pneumonia that is less expensive and more effective than those currently used in Brazil is being tested in human patients.

31 Mar 2020

Investigational oral form of treatment offers hope for adults with acromegaly

Adults who need medical maintenance treatment of the growth hormone disorder acromegaly respond well to an investigational oral form of the drug octreotide, investigators of the Chiasma OPTIMAL study reported.

31 Mar 2020

Evinacumab drug reduces cholesterol levels in patients with rare cholesterol disorder

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol to near-normal levels among patients with a rare cholesterol disorder, meeting the primary endpoint in the first randomized placebo-controlled trial of the drug, which is being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

31 Mar 2020

First-of-its-kind trial identifies a viable target for treating anhedonia

A first-of-its-kind trial has demonstrated that a receptor involved in the brain's reward system may be a viable target for treating anhedonia (or lack of pleasure), a key symptom of several mood and anxiety disorders.

31 Mar 2020

Higher serum EPA levels from prescription fish oil associated with lower cardiovascular events

Higher levels of the omega-3 fatty acid eicosapentaenoic acid (EPA) found in the blood—and not a decrease in triglyceride levels as originally thought—appear to explain the striking reductions in cardiovascular events and deaths seen among people taking 4 grams daily of the prescription fish oil, icosapent ethyl, according to findings from a REDUCE-IT substudy presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

30 Mar 2020

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients.

From AstraZeneca 30 Mar 2020

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Investigational drug vericiguat benefits patients with worsening heart failure

Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Monoclonal antibody reduces LDL cholesterol in adult patients with HoFH

The cholesterol drug alirocumab reduced low-density lipoprotein (LDL) cholesterol by 35.6% compared to placebo in adult patients with homozygous familial hypercholesterolemia (HoFH), according to a phase three clinical trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Taking ticagrelor alone better for patients with complex heart disease

Patients with complex heart disease who stopped taking aspirin three months after the insertion of one or more coronary stents and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor over the same period.

30 Mar 2020

Treatment with ticagrelor alone reduces adverse events in patients with diabetes

Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.

30 Mar 2020

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

People with symptomatic peripheral artery disease who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg (lower extremity revascularization) had a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Experimental drug could offer new treatment for people with chronic heart failure

An experimental drug recently concluded a successful third-phase clinical trial and could potentially offer a new treatment for about 300,000 Canadians who have worsening chronic heart failure.

30 Mar 2020

Intravenous sodium nitrite does not help out-of-hospital cardiac arrest patients

Among patients who had an out-of-hospital cardiac arrest, intravenous sodium nitrite given by paramedics during resuscitation did not significantly improve their chances of being admitted to or discharged from the hospital alive, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

29 Mar 2020

UC Davis launches two clinical trials to evaluate treatments for COVID-19

UC Davis Health has two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.

27 Mar 2020

Study contradicts theory that daily aspirin prevents dementia symptoms

Scientists have disproven the theory that taking a low dose of daily aspirin reduces cognitive symptoms of dementia.

25 Mar 2020

German scientists test TB vaccine against coronavirus

The coronavirus disease (COVID-19) had taken a toll on the world, affecting 168 countries and more than 417,000 people. So far, more than 18,600 people have died due to complications of the disease. Scientists across the globe race to develop the first vaccine against the novel coronavirus.

24 Mar 2020

Clinical trial launched to investigate safety and efficacy of antiviral drug for COVID-19

Physician-scientists at four University of California Health medical centers -- UC San Diego Health, UC San Francisco, UC Irvine Health and UC Davis Health -- have begun recruiting participants for a Phase II clinical trial to investigate the safety and efficacy of treating adult patients with COVID-19 with remdesivir, an antiviral drug that has shown activity in animal models and human clinical trials of SARS-CoV, MERS-CoV, Ebola, Marburg and other viruses.

24 Mar 2020

Placebo News and Research

Stem cells used to combat COVID-19 pneumonia

FDA to trial malaria drugs Chloroquine and Hydroxychloroquine for COVID-19

Novel, affordable pneumonia vaccine tested in human patients

Investigational oral form of treatment offers hope for adults with acromegaly

Evinacumab drug reduces cholesterol levels in patients with rare cholesterol disorder

First-of-its-kind trial identifies a viable target for treating anhedonia

Higher serum EPA levels from prescription fish oil associated with lower cardiovascular events

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

Investigational drug vericiguat benefits patients with worsening heart failure

Monoclonal antibody reduces LDL cholesterol in adult patients with HoFH

Taking ticagrelor alone better for patients with complex heart disease

Treatment with ticagrelor alone reduces adverse events in patients with diabetes

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

Experimental drug could offer new treatment for people with chronic heart failure

Intravenous sodium nitrite does not help out-of-hospital cardiac arrest patients

UC Davis launches two clinical trials to evaluate treatments for COVID-19

Study contradicts theory that daily aspirin prevents dementia symptoms

German scientists test TB vaccine against coronavirus

Clinical trial launched to investigate safety and efficacy of antiviral drug for COVID-19

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News